Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Botulinum toxin treatment of spasticity targeted to muscle endplates: an international, randomised, evaluator-blinded study comparing two different botulinum toxin injection strategies for the treatment of upper limb spasticity

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Frequency of different subtypes of cervical dystonia: a prospective multicenter study according to Col-Cap concept

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Complex regional pain syndrome (CRPS)

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiForskning

  3. Interdisciplinary recognizing and managing of drug-induced tardive oromandibular dystonia: two case reports

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Treatment diary for botulinum toxin spasticity treatment: a pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Somatosensory input and oromandibular dystonia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Tiina Rekand
  • Bo Biering-Sörensen
  • Jun He
  • Ole Jakob Vilholm
  • Peter Brøgger Christensen
  • Trandur Ulfarsson
  • Roger Belusa
  • Torbjörn Ström
  • Peter Myrenfors
  • Pascal Maisonobe
  • Torben Dalager
Vis graf over relationer

OBJECTIVES: The therapeutic effects of botulinum neurotoxin (BoNT) are well documented in upper limb spasticity. However, several factors may influence treatment efficacy, including targeting of neuromuscular junctions (NMJs). We examined whether NMJ-targeted BoNT injections were non-inferior, in terms of efficacy, to current injection practices.

DESIGN: Open-label prospective evaluator-blinded study.

SETTING: Conducted across 20 medical centres in Denmark, Finland, Norway and Sweden (24 September 2012 to 11 March 2015).

PARTICIPANTS: Aged ˃18 years with upper limb spasticity (Modified Ashworth Scale [MAS] score of 2 or 3) following stroke or traumatic brain injury, had received ≥2 consecutive BoNT-A treatment cycles (the latest of which was abobotulinumtoxinA [aboBoNT-A]) and needed BoNT-A retreatment (same modality as previous cycle). Patients requiring aboBoNT-A doses >800units were excluded. In total, 88 patients were randomised (intention-to-treat [ITT] population), most were male (n=58/88, 65.9%) and 54/88 (61.4%) completed the study (per protocol [PP] population).

INTERVENTIONS: Randomisation (1:1) to receive a single dose of aboBoNT-A (≤800 U) according to either current clinical practice (300 U/mL) or as an NMJ-targeted injection (100 U/mL).

PRIMARY OUTCOME MEASURE: Proportion of patients with a ≥1 level reduction from baseline in MAS score at week 4 post-injection (responders).

RESULTS: In the ITT population, the proportion of responders at elbow flexors was 72.7% in the current practice group and 56.8% in the NMJ-targeted group (adjusted difference -0.1673 [95% CIs: -0.3630 to 0.0284]; p=0.0986). Similar results were observed in the PP population (69.0% vs 68.0%, respectively, adjusted difference 0.0707 [-0.1948 to 0.3362]; p=0.6052).

CONCLUSIONS: Owing to the limited number of participants, non-inferiority of NMJ-targeted injections could not be determined. However, there was no statistical difference between groups. Larger studies are needed confirm whether the two techniques offer comparable efficacy.

TRIAL REGISTRATION NUMBER: NCT01682148.

OriginalsprogEngelsk
TidsskriftBMJ Open
Vol/bind9
Udgave nummer5
Sider (fra-til)e024340
ISSN2044-6055
DOI
StatusUdgivet - 2019

Bibliografisk note

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 57959687